Skip to main content
SpringerLink
Log in

Istradefylline for Treating Parkinson’s Disease

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 158 Accesses

Abstract

Adenosine is thought to be a neuromodulator or neurotransmitter in the mammalian peripheral tissues and central nervous systems and involved in biological events in mammalian tissues via specific interactions with G-protein-coupled adenosine receptors. Adenosine receptors are classified into four subtypes: A1, A2A, A2B, and A3. In the central nervous system (CNS), adenosine A2A receptors have a selective localization to the basal ganglia in contrast to other adenosine receptor subtypes and as a consequence offer a unique opportunity to modulate the output from the striatum that is believed critical to the occurrence of motor components of Parkinson’s disease (PD). Adenosine A2A receptor antagonists are active in predictive experimental models of PD and appear to be promising as a major non-dopaminergic therapy for PD. Istradefylline is the first adenosine A2A receptor antagonist approved for the treatment of PD and is currently only available in Japan, with the indication of “Improvement of ‘wearing off’ phenomena in patients with PD on concomitant treatment with l-DOPA containing products.” In this literature review, we will summarize the current knowledge from both clinical and nonclinical studies on the effects of adenosine A2A receptor blockade on PD. Also, we will summarize the potential feature aspects of the adenosine A2A receptor antagonist on the CNS functions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci. 2000;20:5848–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Augood SJ, Emson PC. Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. Brain Res Mol Brain Res. 1994;22:204–10.

    Article  CAS  PubMed  Google Scholar 

  • Barzilai A, Melamed E. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson’s disease. Trends Mol Med. 2003;9:126–32.

    Article  CAS  PubMed  Google Scholar 

  • Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep–wake regulation. Prog Neurobiol. 2004;73:379–96.

    Article  CAS  PubMed  Google Scholar 

  • Bonuccelli U. Comparing dopamine agonists in Parkinson’s disease. Curr Opin Neurol. 2003; 16(Suppl 1):S13–9.

    Article  CAS  PubMed  Google Scholar 

  • Brooks DJ, Doder M, Osman S, Luthra SK, Hirani E, Hume S, et al. Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse. 2008;62:671–81.

    Article  CAS  PubMed  Google Scholar 

  • Chen JF. Adenosine receptor control of cognition in normal and disease. Int Rev Neurobiol. 2014;119:257–307.

    Article  PubMed  Google Scholar 

  • DeLong M. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13:281–5.

    Article  CAS  PubMed  Google Scholar 

  • Doyle TP, Lutz RS, Pellegrino JK, Sanders DJ, Arent SM. The effects of caffeine on arousal, response time, accuracy, and performance in division I collegiate fencers. J Strength Cond Res. 2016;30:3228–35.

    Article  PubMed  Google Scholar 

  • El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol. 2001;134:68–77.

    Article  PubMed  PubMed Central  Google Scholar 

  • El Yacoubi M, Costentin J, Vaugeois JM. Adenosine A2A receptors and depression. Neurology. 2003;61:S82–7.

    Article  PubMed  CAS  Google Scholar 

  • Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci. 2003;991:1–14.

    Article  CAS  PubMed  Google Scholar 

  • Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.

    Article  CAS  PubMed  Google Scholar 

  • Ferré S, Rubio A, Fuxe K. Stimulation of adenosine A2 receptors induces catalepsy. Neurosci Lett. 1991;130:162–4.

    Article  PubMed  Google Scholar 

  • Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–52.

    CAS  PubMed  Google Scholar 

  • Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 1999;52:1673–7.

    Article  CAS  PubMed  Google Scholar 

  • Hauser RA, Hubble JP, Truong DD, Istradefylline US-001 Study Group. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297–303.

    Article  CAS  PubMed  Google Scholar 

  • Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177–85.

    Article  PubMed  Google Scholar 

  • Huang ZL, Qu WM, Eguchi N, Chen J-F, Schwarzschild MA, Fredholm BB, et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci. 2005;8:858–9.

    Article  CAS  PubMed  Google Scholar 

  • Huang Z, Zhang Z, Qu WM. Roles of adenosine and its receptors in sleep-wake regulation. Int Rev Neurobiol. 2014;119:349–71.

    Article  PubMed  Google Scholar 

  • Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kadowaki-Horita T, Kobayashi M, Mori A, Jenner P, Kanda T. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology. 2013;230:345–52.

    Article  CAS  PubMed  Google Scholar 

  • Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol. 1994;256:263–8.

    Article  CAS  PubMed  Google Scholar 

  • Kanda T, Jackson MJ, Smith LA, Pearce RKB, Nakamura J, Kase H, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998a;43:507–13.

    Article  CAS  PubMed  Google Scholar 

  • Kanda T, Tashiro T, Kuwana Y, Jenner P. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport. 1998b;9:2857–60.

    Article  CAS  PubMed  Google Scholar 

  • Koga K, Kurokawa M, Ochi M, Nakamura J, Kuwana Y. Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-parkinsonian rats. Eur J Pharmacol. 2000;408:249–55.

    Article  CAS  PubMed  Google Scholar 

  • LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295–302.

    Article  CAS  PubMed  Google Scholar 

  • Matsuura K, Kajikawa H, Tabei K, Satoh M, Kida H, Nakamura N, et al. The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson’s disease. Neurosci Lett. 2018;662:158–61.

    Article  CAS  PubMed  Google Scholar 

  • McCarley RW. Neurobiology of REM and NREM sleep. Sleep Med. 2007;8:302–30.

    Article  PubMed  Google Scholar 

  • Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord. 2010; 25:1437–43.

    Article  PubMed  Google Scholar 

  • Mizuno Y, Kondo T, The Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist Istradefylline reduces daily OFF time in Parkinson’s disease. Mov Disord. 2013;28:1138–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology. 2003;61(Suppl 6):S44–8.

    Article  CAS  PubMed  Google Scholar 

  • Mori A, Shindou T, Ichimura M, Nonaka H, Kase H. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci. 1996;16:605–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nomoto M, Nagai M, Nishikawa N. Clinical nonmotor aspect of A2A antagonist in PD treatment. Int Rev Neurobiol. 2014;119:191–4.

    Article  PubMed  Google Scholar 

  • Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science. 1997;276:1265–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pourcher M, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2012;18:178–84.

    Article  PubMed  Google Scholar 

  • Saki M, Yamada K, Koshimura E, Sasaki K, Kanta T. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:963–72.

    Article  CAS  PubMed  Google Scholar 

  • Shindou T, Mori A, Kase H, Ichimura M. Adenosine A2A receptor enhances GABAA-mediated IPSCs in the rat globus pallidus. J Physiol. 2001;532:423–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. 1999;147:90–5.

    Article  CAS  PubMed  Google Scholar 

  • Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70:2233–40.

    Article  CAS  PubMed  Google Scholar 

  • Suzuki K, Miyamoto M, Miyamoto T, Uchiyama T, Watanabe Y, Suzuki S, et al. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: an open-label, 3-month study. J Neurol Sci. 2017;380:230–3.

    Article  CAS  PubMed  Google Scholar 

  • Takahashi RN, Pamplona FA, Prediger RD. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci. 2008;13:2614–32.

    Article  CAS  PubMed  Google Scholar 

  • Uchida S, Tashiro T, Kawai-Uchida M, Mori A, Jenner P, Kanda T. The adenosine A2A-receptor antagonist Istradefylline enhances the motor response of l-DOPA without worsening dyskinesia in MPTP-treated common marmosets. J Pharmacol Sci. 2014;124:480–5.

    Article  CAS  PubMed  Google Scholar 

  • Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, et al. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. Eur J Pharmacol. 2015a;747:160–5.

    Article  CAS  PubMed  Google Scholar 

  • Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, et al. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of l-DOPA and dopamine agonists in MPTP-treated common marmosets. Eur J Pharmacol. 2015b;766:25–30.

    Article  CAS  PubMed  Google Scholar 

  • Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T. Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacol Biochem Behav. 2013;114–115:23–30.

    Article  PubMed  CAS  Google Scholar 

  • Yamada K, Kobayashi M, Shiozaki S, Ohta T, Mori A, Jenner P, et al. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology. 2014;231:2839–49.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Translational Research Unit, Research and Development Division, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan

    Tomoyuki Kanda

  2. Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Tohon, Japan

    Masahiro Nomoto

Authors
  1. Tomoyuki Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Nomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masahiro Nomoto .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada

    Benoit Mulsant

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Section Editor information

  1. Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  2. Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, Japan

    Toshiharu Nagatsu

  3. Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Akira Nakashima

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Kanda, T., Nomoto, M. (2020). Istradefylline for Treating Parkinson’s Disease. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_361-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_361-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation